Cargando…

Kratom-Induced Cholestatic Liver Injury and Its Conservative Management

Drug-induced liver injury (DILI) is a common cause of hepatotoxicity associated with prescription-based and over-the-counter exposure to medications and herbal supplements. Use of unapproved and inadequately tested herbal supplements can cause DILI. Therefore, thorough history-taking on exposure to...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Christopher T., Iqbal, Umair, Tighe, Sean P., Ahmed, Aijaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440031/
https://www.ncbi.nlm.nih.gov/pubmed/30920318
http://dx.doi.org/10.1177/2324709619836138
_version_ 1783407316099399680
author Fernandes, Christopher T.
Iqbal, Umair
Tighe, Sean P.
Ahmed, Aijaz
author_facet Fernandes, Christopher T.
Iqbal, Umair
Tighe, Sean P.
Ahmed, Aijaz
author_sort Fernandes, Christopher T.
collection PubMed
description Drug-induced liver injury (DILI) is a common cause of hepatotoxicity associated with prescription-based and over-the-counter exposure to medications and herbal supplements. Use of unapproved and inadequately tested herbal supplements can cause DILI. Therefore, thorough history-taking on exposure to herbal supplements must be an integral part of clinical evaluation of DILI. Kratom is an herbal supplement or remedy that has been known for its analgesic effects and has also been used for self-treatment of opiate withdrawals. A 52-year-old man was seen for evaluation of yellow discoloration of the eyes and skin. He reported taking kratom for right shoulder strain for at least a couple of months. On workup, his total bilirubin was noted to be 23.2 mg/dL, which peaked at 28.9 mg/dL. He was noted to have mild elevation of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase. Extensive laboratory tests were ordered and known causes of chronic liver disease ruled out. Magnetic resonance imaging of the abdomen was unremarkable without stigmata of portal hypertension or signs of chronic liver disease. He demonstrated no evidence of coagulopathy or hepatic encephalopathy during his illness. He underwent liver biopsy, which demonstrated histologic evidence of acute cholestatic hepatitis highly suspicious of DILI. He was advised to avoid kratom or other herbal supplements in future and prescribed ursodeoxycholic acid with significant improvement in his liver chemistries. Kratom is associated with significant liver enzymes derangements leading to DILI. Kratom is not approved for use in the United States and should be avoided.
format Online
Article
Text
id pubmed-6440031
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-64400312019-04-03 Kratom-Induced Cholestatic Liver Injury and Its Conservative Management Fernandes, Christopher T. Iqbal, Umair Tighe, Sean P. Ahmed, Aijaz J Investig Med High Impact Case Rep Case Report Drug-induced liver injury (DILI) is a common cause of hepatotoxicity associated with prescription-based and over-the-counter exposure to medications and herbal supplements. Use of unapproved and inadequately tested herbal supplements can cause DILI. Therefore, thorough history-taking on exposure to herbal supplements must be an integral part of clinical evaluation of DILI. Kratom is an herbal supplement or remedy that has been known for its analgesic effects and has also been used for self-treatment of opiate withdrawals. A 52-year-old man was seen for evaluation of yellow discoloration of the eyes and skin. He reported taking kratom for right shoulder strain for at least a couple of months. On workup, his total bilirubin was noted to be 23.2 mg/dL, which peaked at 28.9 mg/dL. He was noted to have mild elevation of aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase. Extensive laboratory tests were ordered and known causes of chronic liver disease ruled out. Magnetic resonance imaging of the abdomen was unremarkable without stigmata of portal hypertension or signs of chronic liver disease. He demonstrated no evidence of coagulopathy or hepatic encephalopathy during his illness. He underwent liver biopsy, which demonstrated histologic evidence of acute cholestatic hepatitis highly suspicious of DILI. He was advised to avoid kratom or other herbal supplements in future and prescribed ursodeoxycholic acid with significant improvement in his liver chemistries. Kratom is associated with significant liver enzymes derangements leading to DILI. Kratom is not approved for use in the United States and should be avoided. SAGE Publications 2019-03-28 /pmc/articles/PMC6440031/ /pubmed/30920318 http://dx.doi.org/10.1177/2324709619836138 Text en © 2019 American Federation for Medical Research http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Fernandes, Christopher T.
Iqbal, Umair
Tighe, Sean P.
Ahmed, Aijaz
Kratom-Induced Cholestatic Liver Injury and Its Conservative Management
title Kratom-Induced Cholestatic Liver Injury and Its Conservative Management
title_full Kratom-Induced Cholestatic Liver Injury and Its Conservative Management
title_fullStr Kratom-Induced Cholestatic Liver Injury and Its Conservative Management
title_full_unstemmed Kratom-Induced Cholestatic Liver Injury and Its Conservative Management
title_short Kratom-Induced Cholestatic Liver Injury and Its Conservative Management
title_sort kratom-induced cholestatic liver injury and its conservative management
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440031/
https://www.ncbi.nlm.nih.gov/pubmed/30920318
http://dx.doi.org/10.1177/2324709619836138
work_keys_str_mv AT fernandeschristophert kratominducedcholestaticliverinjuryanditsconservativemanagement
AT iqbalumair kratominducedcholestaticliverinjuryanditsconservativemanagement
AT tigheseanp kratominducedcholestaticliverinjuryanditsconservativemanagement
AT ahmedaijaz kratominducedcholestaticliverinjuryanditsconservativemanagement